Asia Green Biotechnology Corp.

ASIA

CA04522C1041

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 12:04:38 07/02/2024 am IST			5-day change	1st Jan Change
0.015 ^CAD	+50.00%		-.--%	+50.00%

24/05	Asia Green Biotechnology Corp. Announces Vincent Ghazar Resigns as Director	CI
24/05	Asia Green Biotechnology Corp. Announces Resignation of Vincent Ghazar as Chief Financial Officer	CI

Asia Green Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 22, 2021 at 03:51 am IST

Asia Green Biotechnology Corp. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced net loss was CAD 152,470 compared to CAD 180,564 a year ago. Basic eps - continuing operations was CAD 0 compared to basic loss per share from continuing operations of CAD 0.01 a year ago.

Latest news about Asia Green Biotechnology Corp.

Asia Green Biotechnology Corp. Announces Vincent Ghazar Resigns as Director	25/05	CI
Asia Green Biotechnology Corp. Announces Resignation of Vincent Ghazar as Chief Financial Officer	25/05	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	24/05	CI
Asia Green Biotechnology Corp. Announces Discontinuation of Any Further Activities in Asia, in Particular, in Cambodia and Thailand	13/04	CI
Burton Growers Ltd. & Green Sight Agri-Holdings Inc. entered into a non-binding letter of intent to acquire Asia Green Biotechnology Corp. for CAD 4 million in a reverse merger transaction.	21/02	CI
Asia Green Biotechnology Corp. announced that it expects to receive CAD 1.5 million in funding	20/02	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/11	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
Asia Green Biotechnology Corp. Announces Passing of Johannes Kingma, Director	15/23/15	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/23/31	CI
Asia Green Biotechnology Corp. Partners with Pathway Rx Inc. to Pursue Clinical Trials Activities in the Development of A Migraine Treatment Utilizing Cannabis and Hemp Extracts Controlled by Pathway Inc	27/23/27	CI
Asia Green Biotechnology Corp. Announces Resignation of Daryl Hudson as Director	27/23/27	CI
Asia Green Biotechnology Corp. Auditor Raises 'Going Concern' Doubt	06/23/06	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	06/23/06	CI
Asia Green Biotechnology Corp. Proceeds to Next Phase of Migraine Clinical Study	24/23/24	CI
Asia Green Biotechnology Corp. Proceeding to Next Phase of Migraine Clinical Study; Extending Financing Arrangement	24/23/24	MT
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/22/28	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	27/22/27	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	18/22/18	CI
Asia Green Biotechnology Corp. Auditor Raises 'Going Concern' Doubt	02/22/02	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	02/22/02	CI
2,003,090 Common Shares of Asia Green Biotechnology Corp. are subject to a Lock-Up Agreement Ending on 24-JAN-2022.	24/22/24	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	26/21/26	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021	31/21/31	CI
Asia Green Biotechnology Corp. to Fund Initial Human Clinical Trials for Treatment of Migraine Conditions	10/21/10	CI

Chart Asia Green Biotechnology Corp.

Duration

Period

More charts

Company Profile

Asia Green Biotechnology Corp. is a Canada-based early-stage international agro-technology company. The Company is focused on the development, evaluation, testing, application and, ultimately, supply to the market of organic hybridization technology and certain products derived from that technology (the Technology). The Company is engaged in planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of the license agreement with InPlanta Biotechnology Inc. (InPlanta) and the evaluation and development of medicinal and related cannabinoid extracts under the terms of license agreements with Swysh Inc. (Swysh), and Pathway Rx Corp (Pathway Rx). It is in the process of establishing and implementing research and development programs in Cambodia and Thailand and continues to evaluate the potential to expand its business operations to other countries in the region.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
ASIA GREEN BIOTECHNOLOGY CORP.	+50.00%	399K
DONG-E-E-JIAO CO.,LTD.	+42.07%	6.28B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.20%	4.25B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+5.38%	3.36B
TASLY PHARMACEUTICAL GROUP CO., LTD	-16.98%	2.96B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-5.82%	2.45B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+45.47%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-12.67%	1.61B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-3.91%	1.6B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+44.56%	1.51B